EUVIMEDEUVIMED entdecken
Crossref

Immunotherapy of M2 macrophage derived from exosome-based nanoparticles for spinal cord injury

Lu Bai, Jinpeng Gao, Peng Zhang, Sen Lin, Chuanjie Zhang

International Immunopharmacology · 2024

DOI: 10.1016/j.intimp.2024.111983 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Lu Bai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, PR China. Hauptthemen laut MEDLINE: Exosomes, Spinal Cord Injuries, Macrophages, Nanoparticles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Developing biomimetic nanoparticles without off-target side-effects remains a major challenge in spinal cord injury (SCI) immunotherapy. In this paper, we have conducted a drug carrier which is biocompatible macrophages-exocytosed exosome-biomimetic manganese (Mn)-iron prussian blue analogues (MPBs) for SCI immunotherapy. Exosome-sheathed MPBs (E-MPBs) exhibit promoted microglia accumulation, alleviation from H2O2-induced microenvironment and inhibition of apoptosis and inflammation in vitro. In addition, E-MPBs possessed significant tissue repair and neuroprotection in vivo. These properties endowed E-MPBs with great improvement in vivo in function recovery, resulting in anti-neuroinflammation activity and excellent biocompatibility in mice SCI model. As a promising treatment for efficient SCI immunotherapy, these results demonstrate the use of exosome-sheathed biomimetic nanoparticles exocytosed by anti-inflammation cells is feasible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExosomesSpinal Cord InjuriesMacrophagesNanoparticlesImmunotherapyAnimalsMiceFerrocyanidesMice, Inbred C57BLDisease Models, AnimalHumansMicrogliaRAW 264.7 CellsApoptosis

Stichwörter der Autor:innen

ExosomesImmune responseMn-iron prussian blue analoguesSpinal cord injury

Substanzen

ferric ferrocyanideFerrocyanides

Autor:innen und Institutionen

  • Department of Gastroenterology, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, PR China.
  • Department of Orthopedics, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, PR China.
  • Department of Orthopedics, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, PR China. Electronic address: aldrin_lin@163.com.
  • Department of Orthopedics, Third Affiliated Hospital of Jinzhou Medical University, Jinzhou, PR China. Electronic address: zhangchuanjie96@163.com.

Zitieren

APA

Bai, L., Gao, J., Zhang, P., Lin, S., & Zhang, C. (2024). Immunotherapy of M2 macrophage derived from exosome-based nanoparticles for spinal cord injury. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.111983

Vancouver

Bai L, Gao J, Zhang P, Lin S, Zhang C. Immunotherapy of M2 macrophage derived from exosome-based nanoparticles for spinal cord injury. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.111983

BibTeX
@article{Bai2024,
  author = {Bai, Lu and Gao, Jinpeng and Zhang, Peng and Lin, Sen and Zhang, Chuanjie},
  title = {Immunotherapy of M2 macrophage derived from exosome-based nanoparticles for spinal cord injury},
  journal = {International Immunopharmacology},
  year = {2024},
  doi = {10.1016/j.intimp.2024.111983}
}
Kostenlos starten →